This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US FTC says in-house insulin pricing suit should continue

( March 13, 2025, 23:31 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission opposed Express Scripts and other pharmacy benefit managers’ request for preliminarily injunction against an administrative proceeding initiated by the FTC pending an appeal. “Plaintiffs’ lead argument is that FTC commissioners and the commission’s administrative law judge have unconstitutional removal protections. But plaintiffs overlook that a party challenging removal protections cannot show entitlement to relief without demonstrating that the removal protections had some prejudicial effect on the plaintiff, and plaintiffs here do not even attempt to make such a showing,” it told an appeals court. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections